Pituitary apoplexy

Summary

Pituitary apoplexy (MONDO:0006908) is a disease. A subtype of pituitary gland infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 41

Clinical features

Signs & symptoms

Clinical features (HPO)

41 HPO clinical features (Orphanet curated; top 41 by frequency):

HPO ID	Term	Frequency
HP:0030521	Bitemporal hemianopia	Very frequent (80-99%)
HP:0030907	Thunderclap headache	Very frequent (80-99%)
HP:0000651	Diplopia	Frequent (30-79%)
HP:0000802	Impotence	Frequent (30-79%)
HP:0000815	Hypergonadotropic hypogonadism	Frequent (30-79%)
HP:0000822	Hypertension	Frequent (30-79%)
HP:0000876	Oligomenorrhea	Frequent (30-79%)
HP:0001943	Hypoglycemia	Frequent (30-79%)
HP:0002017	Nausea and vomiting	Frequent (30-79%)
HP:0002315	Headache	Frequent (30-79%)
HP:0002615	Hypotension	Frequent (30-79%)
HP:0002893	Pituitary adenoma	Frequent (30-79%)
HP:0002902	Hyponatremia	Frequent (30-79%)
HP:0006824	Cranial nerve paralysis	Frequent (30-79%)
HP:0008202	Reduced circulating prolactin concentration	Frequent (30-79%)
HP:0008245	Pituitary hypothyroidism	Frequent (30-79%)
HP:0011748	Adrenocorticotropic hormone deficiency	Frequent (30-79%)
HP:0030591	Abnormal kinetic perimetry test	Frequent (30-79%)
HP:0030595	Abnormal static automated perimetry test	Frequent (30-79%)
HP:0000508	Ptosis	Occasional (5-29%)
HP:0000613	Photophobia	Occasional (5-29%)
HP:0000622	Blurred vision	Occasional (5-29%)
HP:0000824	Decreased response to growth hormone stimulation test	Occasional (5-29%)
HP:0000870	Increased circulating prolactin concentration	Occasional (5-29%)
HP:0000980	Pallor	Occasional (5-29%)
HP:0001259	Coma	Occasional (5-29%)
HP:0001945	Fever	Occasional (5-29%)
HP:0002921	Abnormality of the cerebrospinal fluid	Occasional (5-29%)
HP:0007663	Reduced visual acuity	Occasional (5-29%)
HP:0011499	Mydriasis	Occasional (5-29%)
HP:0012378	Fatigue	Occasional (5-29%)
HP:0040075	Hypopituitarism	Occasional (5-29%)
HP:0100829	Galactorrhea	Occasional (5-29%)
HP:0000845	Elevated circulating growth hormone concentration	Very rare (<1-4%)
HP:0000863	Central diabetes insipidus	Very rare (<1-4%)
HP:0001262	Excessive daytime somnolence	Very rare (<1-4%)
HP:0001289	Confusion	Very rare (<1-4%)
HP:0001895	Normochromic anemia	Very rare (<1-4%)
HP:0002339	Abnormal caudate nucleus morphology	Very rare (<1-4%)
HP:0003118	Increased circulating cortisol level	Very rare (<1-4%)
HP:0100661	Trigeminal neuralgia	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	pituitary apoplexy
Mondo ID	MONDO:0006908
EFO	EFO:1001108
MeSH	D010899
Orphanet	95613
DOID	DOID:1129
ICD-11	1938573221
NCIT	C26853
SNOMED CT	237701005
UMLS	C0032001
MedGen	18489
GARD	0019287
MedDRA	10056447
Is cancer (heuristic)	no

Also known as: pituitary gland apoplexy

Disease family

This is a subtype of pituitary gland infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › pituitary gland disorder › necrosis of pituitary › pituitary gland infarction › pituitary apoplexy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.